The CEO of BioMarin is Exercising Options

By Carrie Williams

Yesterday, the CEO of BioMarin, Jean Jacques Bienaime, exercised options of BioMarin for $32.25K.

Over the last month, Jean Jacques Bienaime has reported another 5 Buy trades on BMRN for a total of $1.22M.

Based on BioMarin’s latest earnings report for the quarter ending December 31, the company posted quarterly revenue of $364 million and GAAP net loss of $51.39 million. In comparison, last year the company earned revenue of $300 million and had a GAAP net loss of $16.29 million. The company has a one-year high of $100.51 and a one-year low of $77.05. Currently, BioMarin has an average volume of 1.1M.

27 different firms, including Barclays and BMO Capital, currently also have a Buy rating on the stock. Based on 11 analyst ratings, the analyst consensus is Strong Buy with an average price target of $120.36, reflecting a -32.6% downside. Starting in March 2018, BMRN received 6 Buy ratings in a row.

The insider sentiment on BioMarin has been positive according to 111 insider trades in the past three months. This sentiment is slightly higher than the average sentiment of company insiders in this sector.

Company insider trades’ information is brought to you by the DailyInsider, a proprietary algorithm that analyzes insider trading activity to detect the most attractive trading opportunities. To subscribe to the DailyInsider visit this page.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

BioMarin Pharmaceutical, Inc. is a biotechnology company that develops and commercializes innovative pharmaceuticals for serious diseases and medical conditions. Its products include Naglazyme, Kuvan, Aldurazyme, Firdapse and VIMIZIM. The company was founded by Christopher M. Starr and Grant W.